Company intelligence / Profile preview

OV-SPV 2

Ownership: Private
Development stage: Other

Overview

OV-SPV 2 is a biotechnology entity focused on the development of next-generation oncolytic virus therapies for the treatment of solid tumors. The company operates as a specialized vehicle designed to advance specific viral immunotherapy assets through early-stage research and development. Its primary focus involves engineering viruses to selectively infect and lyse cancer cells while simultaneously stimulating a systemic anti-tumor immune response. By leveraging advanced genetic engineering, OV-SPV 2 aims to overcome the immunosuppressive microenvironment typical of aggressive cancers like glioblastoma.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyGene therapy
Industry: Biotech

Beyond the preview

Go deeper on OV-SPV 2.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OV-SPV 2.

Explore the full profile